Liyuan Hao

The current status and future of PD-L1 in liver cancer

Liyuan Hao, Shenghao Li, Jiali Deng et al. · Frontiers in Immunology · 2023 · 52 citations · Full text

Medicine, Immunology, Oncology +17

Cisplatin promotes the expression level of PD-L1 in the microenvironment of hepatocellular carcinoma through YAP1

Shenghao Li, Jingmin Ji, Zhiqin Zhang et al. · Molecular and Cellular Biochemistry · 2020 · 51 citations

Medicine, Cancer Biology, Oncology +14

Dihydroartemisinin reduced lipid droplet deposition by YAP1 to promote the anti-PD-1 effect in hepatocellular carcinoma

Liyuan Hao, Yinglin Guo, Qing Peng et al. · Phytomedicine · 2021 · 34 citations

Medicine, Cancer Biology, Oncology +13

Dihydroartemisinin broke the tumor immunosuppressive microenvironment by inhibiting <scp>YAP1</scp> expression to enhance <scp>anti‐PD</scp>‐1 efficacy

Qing Peng, Shenghao Li, Xinli Shi et al. · Phytotherapy Research · 2022 · 32 citations

Medicine, Cancer Biology, Oncology +17

Anti‑malarial drug dihydroartemisinin downregulates the expression levels of <i>CDK1</i> and <i>CCNB1</i> in liver cancer

Liyuan Hao, Shenghao Li, Qing Peng et al. · Oncology Letters · 2021 · 29 citations · Full text

Medicine, Molecular Biology, Oncology +17